Tylenol vs Revvity
Side-by-side comparison of AI visibility scores, market position, and capabilities
Global #1 OTC acetaminophen brand owned by Kenvue (NYSE: KVUE, J&J 2023 spinoff at $41B); Kimberly-Clark $48.7B Kenvue acquisition pending close H2 2026 competing with Advil and store brand for OTC pain relief market.
About
Tylenol is a global over-the-counter acetaminophen (paracetamol) pain relief and fever reducer brand — owned by Kenvue (NYSE: KVUE), the consumer health company spun off from Johnson & Johnson in May 2023 at a $41 billion IPO valuation, and subject to a pending $48.7 billion acquisition by Kimberly-Clark announced in November 2025 (expected to close second half 2026) — providing consumers with the world's most widely used analgesic through product lines including Tylenol Extra Strength, Tylenol PM, Tylenol Rapid Release Gels, Tylenol Children's, and Tylenol Arthritis Pain for adults and pediatric pain and fever management. Generating approximately $2 billion in annual retail sales as one of Kenvue's flagship brands alongside Neutrogena, Band-Aid, Listerine, and Zyrtec, Tylenol is the #1 recommended pain reliever by doctors and pharmacists in the United States. Originally marketed by McNeil Laboratories (acquired by J&J in 1959), the brand was approved for OTC sale in 1960.
Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.
About
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.